These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12680142)

  • 1. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
    Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
    Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy.
    Hansen BD; Schmidt H; von der Maase H; Sjoegren P; Agger R; Hokland M
    Acta Oncol; 2006; 45(4):400-5. PubMed ID: 16760175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P
    Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
    Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
    Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
    Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
    Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
    Konjević G; Jović V; Vuletić A; Radulović S; Jelić S; Spuzić I
    Eur J Clin Invest; 2007 Nov; 37(11):887-96. PubMed ID: 17973783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
    Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
    Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of T-cell cytokine production and NK-cell function by IL-2, IFN-alpha and histamine treatment during remission of non-Hodgkin's lymphoma.
    Ahlberg R; MacNamara B; Andersson M; Zheng C; Svensson A; Holm G; Hansson M; Porwit-MacDonald A; Björkholm M; Sundblad A
    Hematol J; 2003; 4(5):336-41. PubMed ID: 14502258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine in immunotherapy of advanced melanoma: a pilot study.
    Hellstrand K; Naredi P; Lindner P; Lundholm K; Rudenstam CM; Hermodsson S; Asztély M; Hafström L
    Cancer Immunol Immunother; 1994 Dec; 39(6):416-9. PubMed ID: 8001030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro Shwartzman reaction-like response is augmented age-dependently in human peripheral blood mononuclear cells.
    Motegi A; Kinoshita M; Sato K; Shinomiya N; Ono S; Nonoyama S; Hiraide H; Seki S
    J Leukoc Biol; 2006 Mar; 79(3):463-72. PubMed ID: 16387840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
    Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
    J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.
    Donskov F; Hokland M; Marcussen N; Torp Madsen HH; von der Maase H
    Br J Cancer; 2006 Jan; 94(2):218-26. PubMed ID: 16434984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine and cytokine therapy.
    Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
    Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
    Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
    Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.